Description
LuciTrelag 100 MG (Trelagliptin) is a once-weekly, selective dipeptidyl peptidase-4 (DPP-4) inhibitor an orally administered incretin enhancer that reversibly inhibits the DPP-4 enzyme to prevent the rapid proteolytic degradation of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby potentiating glucose-dependent insulin secretion from pancreatic beta cells and suppressing inappropriate glucagon release from pancreatic alpha cells without causing hypoglycaemia as monotherapy supplied as a 100 mg oral tablet in a pack of 16 tablets (providing 16 weeks of once-weekly therapy per box) and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd., Laos. Its active ingredient, trelagliptin, is distinguished from all other commercially available DPP-4 inhibitors linagliptin, sitagliptin, saxagliptin, alogliptin, and vildagliptin by its exceptional terminal plasma half-life of approximately 65 hours, which enables once-weekly rather than once-daily oral dosing while maintaining DPP-4 inhibition exceeding 80% throughout the full 168-hour (7-day) dosing interval at steady state.
In the pivotal 24-week Phase 3 monotherapy trial in Japanese adults with type 2 diabetes mellitus, trelagliptin 100 mg once weekly achieved a mean HbA1c reduction of 0.87% from baseline versus 0.11% with placebo (p<0.0001), with weight neutrality and no hypoglycaemia as monotherapy. The originator brand Zafatek® (Takeda Pharmaceutical Company Limited), approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in March 2015, was the world’s first once-weekly oral antidiabetic agent ever approved globally a landmark in type 2 diabetes pharmacotherapy. Searching for LuciTrelag 100 MG Trelagliptin? Mediaid Pharmacy lists this product across its diabetes medicines and Lucius Pharmaceuticals portfolios and ships it worldwide.
Basic Product Information of LuciTrelag 100 MG (Trelagliptin)
| Brand Name | LuciTrelag 100 MG (Trelagliptin) |
| Product Name | LuciTrelag |
| Generic Name | Trelagliptin |
| Drug Class | Dipeptidyl Peptidase-4 (DPP-4) Inhibitor; Once-Weekly DPP-4 Inhibitor; Incretin Enhancer; Oral Antidiabetic Agent; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Oral Hypoglycaemic Agent; Pancreatic Beta Cell Stimulant (Glucose-Dependent); DPP-4 Enzyme Inhibitor; GLP-1 and GIP Stabiliser; Long-Acting DPP-4 Inhibitor |
| Formulation | Oral Tablet |
| Available Strengths | 100 mg trelagliptin per tablet |
| Available Pack Size | 16 tablets per box (16 weeks approximately 4 months of once-weekly therapy per carton) |
| Recommended Dose & Administration | Standard dose: 100 mg orally once weekly, administered on the same day each week, at any time of day, with or without food. Renal impairment: Dose reduction to 50 mg once weekly is required in patients with moderate-to-severe renal impairment (eGFR <30 mL/min/1.73 m²); LuciTrelag is not recommended in patients with end-stage renal disease (ESRD) requiring dialysis due to insufficient pharmacokinetic and clinical data in this population. Hepatic impairment: No dose adjustment required in mild to moderate hepatic impairment; use with caution in severe hepatic impairment. Elderly patients: No dose adjustment required based on age alone; assess renal function as clinically indicated before prescribing. Administration: Swallow tablet whole with water. Designate a fixed day of the week for dosing (for example, every Monday) to maximise adherence. If a dose is missed, take it as soon as remembered on the same day; if not remembered until the following day, skip the missed dose and resume the once-weekly schedule on the next designated dosing day do not take two doses within the same week. |
| Primary Indications | Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other oral antidiabetic agents (metformin, sulfonylurea, thiazolidinedione, SGLT2 inhibitor) or basal insulin when existing treatment does not achieve adequate glycaemic control. Treatment decisions must account for baseline HbA1c, renal function, cardiovascular risk profile, concomitant antidiabetic medications, hypoglycaemia risk, and patient adherence profile always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting therapy. |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos |
| Originator Reference Brand | Zafatek® (trelagliptin succinate tablets 100 mg, developed and marketed by Takeda Pharmaceutical Company Limited approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in March 2015 as the world’s first once-weekly oral DPP-4 inhibitor and the first once-weekly oral antidiabetic agent approved globally for type 2 diabetes in adults). Zafatek® contains trelagliptin as the active pharmaceutical ingredient in the same once-weekly DPP-4 inhibitor drug class. LuciTrelag is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store below 30°C (86°F) in a dry place, protected from moisture and direct sunlight. Keep in the original blister packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and blister. |
How LuciTrelag (Trelagliptin) Works: Once-Weekly DPP-4 Inhibition and Incretin Enhancement in Type 2 Diabetes
Trelagliptin is a selective and reversible inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme a serine protease expressed on the surface of endothelial cells, kidney tubular epithelium, T lymphocytes, and intestinal epithelial cells that rapidly cleaves and inactivates endogenous incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) within 1 to 2 minutes of their release into the portal circulation. GLP-1 is secreted by intestinal L cells in the distal ileum and colon in response to food ingestion, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying to reduce postprandial glucose excursions, and activating central satiety pathways in the hypothalamus and brainstem.
GIP is secreted by duodenal K cells in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion and promoting peripheral glucose disposal. In type 2 diabetes mellitus, the incretin effect which normally accounts for 50 to 70% of postprandial insulin secretion in healthy individuals is markedly attenuated, partly due to accelerated DPP-4-mediated incretin degradation that further shortens the already impaired GLP-1 and GIP half-lives to less than 2 minutes in the portal and systemic circulation. By occupying the DPP-4 active site and blocking access to the N-terminal dipeptide cleavage site on GLP-1 and GIP, trelagliptin extends the plasma half-lives of intact, biologically active GLP-1 and GIP by 2- to 3-fold reconstituting a near-physiological incretin response that is strictly glucose-dependent, meaning insulin secretion is augmented only in the presence of elevated plasma glucose, automatically switching off when glucose normalises and thereby eliminating the glucose-independent insulin secretagogue mechanism that produces hypoglycaemia with sulfonylureas and meglitinides.
The pharmacokinetic basis for once-weekly dosing is the defining characteristic that distinguishes trelagliptin from all other DPP-4 inhibitors in clinical use. Trelagliptin’s terminal plasma half-life is approximately 65 hours compared to approximately 12 hours for linagliptin, approximately 12.4 hours for sitagliptin, approximately 2.5 hours for saxagliptin (active metabolite: 3.1 hours), and approximately 26 hours for alogliptin a pharmacokinetic parameter that directly enables once-weekly rather than once-daily dosing.
At steady state following once-weekly 100 mg administration, trelagliptin maintains DPP-4 inhibition exceeding 80% throughout the entire 168-hour (7-day) dosing interval the minimum threshold for clinically meaningful incretin enhancement and glucose lowering without accumulation to adverse event-associated drug exposure levels. Pharmacokinetically, following oral administration of trelagliptin 100 mg, peak plasma concentration (Tmax) is reached at approximately 3 hours, apparent oral bioavailability is approximately 90%, and plasma protein binding is approximately 37% (characteristically low compared to linagliptin’s >99% protein binding).
The clinical implication of predominantly renal elimination is that trelagliptin exposure (area under the curve, AUC) increases with progressive renal impairment: dose reduction to 50 mg once weekly is required at eGFR <30 mL/min/1.73 m², and trelagliptin is not recommended in end-stage renal disease (ESRD) requiring dialysis due to insufficient pharmacokinetic data an important clinical distinction from linagliptin, which requires no dose adjustment at any stage of renal impairment. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.
LuciTrelag (Trelagliptin): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 diabetes mellitus (T2DM) in adults as an adjunct to diet and exercise, used as monotherapy or in combination with metformin, sulfonylurea, thiazolidinedione, SGLT2 inhibitor, or basal insulin when single-agent therapy is insufficient to achieve adequate glycaemic control. Trelagliptin (Zafatek®) was approved by Japan’s PMDA in March 2015 as the world’s first once-weekly oral antidiabetic. LuciTrelag 100 MG is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos. |
| Dosing and Administration | Standard dose: 100 mg once weekly (eGFR ≥30 mL/min/1.73 m²). Renal dose reduction: 50 mg once weekly (eGFR <30 mL/min/1.73 m²). ESRD or dialysis: Not recommended (insufficient data). Administer orally on a fixed day each week, at any time of day, with or without food. Do not double-dose if a dose is missed resume regular weekly schedule on the next designated dosing day. |
| Common Adverse Reactions | Nasopharyngitis and upper respiratory tract infections (URTIs) are the most commonly reported adverse reactions with trelagliptin in Phase 3 clinical trials. Urinary tract infections (UTIs) have been reported. Hypoglycaemia does not occur with LuciTrelag as monotherapy due to its strictly glucose-dependent insulin secretion mechanism; when combined with a sulfonylurea or basal insulin, hypoglycaemia risk increases and dose reduction of the sulfonylurea or insulin should be considered. Serious adverse reactions reported as class effects for DPP-4 inhibitors include severe hypersensitivity reactions (anaphylaxis, angioedema, exfoliative skin conditions) and acute pancreatitis discontinue LuciTrelag immediately if either is suspected. Counsel patients regarding hypoglycaemia risk when on combination therapy, hypersensitivity symptoms, and signs of pancreatitis. |
| Drug Interactions | Insulin secretagogues and basal insulin: Concomitant use of trelagliptin with a sulfonylurea (glimepiride, glibenclamide, glipizide) or basal insulin (insulin glargine, insulin detemir) increases hypoglycaemia risk consider dose reduction of the sulfonylurea or insulin when adding LuciTrelag to existing therapy. P-glycoprotein (P-gp) substrates: Trelagliptin is a P-gp substrate; assess potential pharmacokinetic interactions with P-gp inhibitors or inducers in polypharmacy patients. Metformin: No clinically relevant pharmacokinetic interaction; co-administration is supported. SGLT2 inhibitors and thiazolidinediones: No clinically relevant pharmacokinetic interaction reported. Other DPP-4 inhibitors: Do not combine LuciTrelag (Trelagliptin) with another DPP-4 inhibitor (sitagliptin, linagliptin, saxagliptin, alogliptin, vildagliptin) as additive DPP-4 inhibition provides no additional glycaemic benefit and increases the risk of adverse effects. |
| Renal Impairment | LuciTrelag (Trelagliptin) 100 mg once weekly is used in patients with mild renal impairment (eGFR 60–89 mL/min/1.73 m²) without dose adjustment. Dose reduction to 50 mg once weekly is required in patients with moderate-to-severe renal impairment (eGFR <30 mL/min/1.73 m²), as trelagliptin is primarily eliminated renally and its AUC increases with declining renal function. LuciTrelag (Trelagliptin) is not recommended in patients with end-stage renal disease (ESRD) or on haemodialysis or peritoneal dialysis due to insufficient pharmacokinetic and clinical data. This renal dose-adjustment requirement is an important clinical distinction from linagliptin (which requires no renal dose adjustment at any CKD stage due to biliary/intestinal elimination), sitagliptin (dose reduction at eGFR <45 mL/min/1.73 m²), and alogliptin (dose reduction at eGFR <60 mL/min/1.73 m²). Consult the treating endocrinologist and nephrologist for individualised guidance. |
| Pregnancy & Lactation | LuciTrelag (Trelagliptin) is not recommended during pregnancy. Adequate and well-controlled studies in pregnant women are not available; animal reproductive toxicity studies demonstrated developmental effects at high trelagliptin exposures. Insulin remains the preferred antidiabetic agent during pregnancy for type 2 diabetes mellitus. Breastfeeding is not recommended during trelagliptin treatment, as it is unknown whether trelagliptin is excreted in human milk. If pregnancy occurs during LuciTrelag treatment, notify the treating endocrinologist immediately and transition to insulin therapy or another pregnancy-appropriate antidiabetic regimen per specialist guidance. |
Who Should Use LuciTrelag (Trelagliptin)?
LuciTrelag (Trelagliptin) is indicated for adults with type 2 diabetes mellitus requiring improved glycaemic control as an adjunct to diet and exercise with a particular clinical and practical advantage for patient populations where once-weekly oral dosing confers measurable adherence benefits over daily antidiabetic regimens.
First, adults with type 2 diabetes mellitus who struggle with adherence to daily oral antidiabetic therapy represent the primary population in whom trelagliptin’s once-weekly dosing schedule delivers a clinically meaningful practical advantage. Medication non-adherence in type 2 diabetes is estimated to affect 40 to 50% of patients on chronic daily oral antidiabetic regimens, and non-adherence is directly associated with suboptimal HbA1c control and increased risk of diabetes complications. A single 100 mg dose of trelagliptin maintains DPP-4 inhibition above 80% throughout the entire 168-hour (7-day) dosing interval, delivering the same mechanistic DPP-4 enzyme inhibition achieved by once-daily DPP-4 inhibitors without requiring daily self-dosing discipline. In the pivotal 24-week Phase 3 monotherapy trial, trelagliptin 100 mg once weekly achieved HbA1c reduction of 0.87% from baseline versus 0.11% with placebo (p<0.0001), with weight neutrality and no monotherapy hypoglycaemia.
Second, adults with type 2 diabetes on complex polypharmacy regimens including patients already taking multiple daily medications for cardiovascular disease, hypertension, or dyslipidaemia benefit from reducing their daily tablet count by substituting a daily DPP-4 inhibitor with LuciTrelag (Trelagliptin) 100 MG once weekly, cutting their DPP-4 inhibitor dosing occasions from 365 to 52 per year.
Third, adults with type 2 diabetes for whom minimising hypoglycaemia risk is a clinical priority including older adults, patients with hypoglycaemia unawareness, patients who drive professionally, and patients with demanding occupational or safety-critical roles benefit from trelagliptin’s glucose-dependent insulin secretion mechanism, which produces no hypoglycaemia as monotherapy.
Fourth, diabetes specialist centres, endocrinology clinics, and hospital pharmacy departments managing large type 2 diabetes outpatient cohorts in regions where improving patient adherence is a documented clinical challenge represent a key institutional procurement population for LuciTrelag (Trelagliptin) 100 MG.
Endocrinology centres co-sourcing LuciTrelag alongside other oral antidiabetic or specialty diabetes medicines can browse the Mediaid Pharmacy diabetes medicines portfolio for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciTrelag 100 MG (Trelagliptin)
Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centres, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. LuciTrelag 100 MG (Trelagliptin), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as oral tablets in a 16-tablet pack a once-weekly dosing format providing 16 weeks (approximately 4 months) of continuous DPP-4 inhibitor therapy per carton with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The once-weekly oral tablet formulation of LuciTrelag supports convenient self-administration on a fixed day of the week with or without food, with no injection device, no daily dose titration, and no renal dose calculation required in patients with normal to mildly reduced renal function making procurement, dispensing, and patient education straightforward for diabetes clinics and pharmacy departments co-sourcing once-weekly oral DPP-4 inhibitor therapy for type 2 diabetes patient cohorts with varying adherence profiles. Diabetes specialist centres managing complex or polypharmacy type 2 diabetes patients, endocrinology programmes seeking to improve patient adherence through once-weekly oral antidiabetic options, hospital pharmacy departments co-sourcing oral antidiabetic agents for outpatient use, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciTrelag Trelagliptin stock availability, current pricing, and international delivery timelines to their country.
Procurement teams co-sourcing LuciTrelag with other specialty diabetes or metabolic medicines can browse the complete Mediaid Pharmacy diabetes medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose LuciTrelag (Trelagliptin) from Mediaid Pharmacy?
LuciTrelag (Trelagliptin) delivers a single 100 mg once-weekly oral dose the only DPP-4 inhibitor available in a weekly rather than daily dosing format a pharmacokinetic achievement enabled by trelagliptin’s exceptional terminal plasma half-life of approximately 65 hours, which sustains DPP-4 inhibition above 80% for the complete 168-hour dosing interval between doses.
From an adherence perspective, the transition from a daily DPP-4 inhibitor to LuciTrelag 100 MG once weekly reduces DPP-4 inhibitor dosing occasions from 365 per year to 52 per year a 7-fold reduction in dosing events that translates directly to improved long-term medication adherence in patient populations where daily polypharmacy burden is a recognised barrier to sustained glycaemic control. Patient-reported adherence studies consistently show that once-weekly dosing regimens achieve higher adherence rates than once-daily regimens across chronic disease classes, and trelagliptin is the first and currently only oral antidiabetic to apply this principle to DPP-4 inhibitor therapy.
From an efficacy standpoint, the pivotal 24-week Phase 3 monotherapy trial of trelagliptin 100 mg once weekly achieved HbA1c reduction of 0.87% from baseline versus 0.11% with placebo (p<0.0001), with weight neutrality and no hypoglycaemia as monotherapy confirming that once-weekly dosing delivers clinically meaningful HbA1c reduction comparable to the 0.4–0.8% reductions observed with once-daily DPP-4 inhibitors (linagliptin: 0.69%; sitagliptin: 0.61–0.79%; alogliptin: 0.52–0.59%) in Phase 3 monotherapy trials.
From a packaging and procurement perspective, the LuciTrelag 100 MG 16-tablet pack provides 16 weeks (approximately 4 months) of uninterrupted once-weekly DPP-4 inhibitor therapy per box compared to 120 to 140 tablets required for four months of a daily DPP-4 inhibitor simplifying inventory management, reducing dispensing frequency, and lowering per-patient dispensing cost for diabetes specialist centres and hospital pharmacy departments managing large outpatient type 2 diabetes cohorts.
LuciTrelag, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, delivers the same active pharmaceutical ingredient trelagliptin and the same once-weekly 100 mg tablet format as the originator Zafatek® (Takeda Pharmaceutical Company Limited), sourced through Mediaid Pharmacy with worldwide shipping to patients and healthcare providers globally. To source additional Lucius Pharmaceuticals medicines and the full range of diabetes medicines available at Mediaid Pharmacy, browse both portfolios and contact the team for a personalised quotation.
Frequently Asked Questions About LuciTrelag 100 MG (Trelagliptin)
What is LuciTrelag 100 MG (Trelagliptin) used for?
LuciTrelag 100 MG (Trelagliptin) is a once-weekly DPP-4 inhibitor used as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM). It is used as monotherapy when other antidiabetic agents are not tolerated or contraindicated, and as add-on combination therapy with metformin, sulfonylureas, thiazolidinediones, or SGLT2 inhibitors when single-agent therapy does not achieve adequate HbA1c control. LuciTrelag (Trelagliptin) works by inhibiting the DPP-4 enzyme, extending the activity of endogenous incretin hormones GLP-1 and GIP to stimulate glucose-dependent insulin secretion and suppress inappropriate glucagon release producing meaningful HbA1c reduction without hypoglycaemia as monotherapy and requiring only once-weekly oral dosing rather than the daily dosing required by all other approved DPP-4 inhibitors. The originator brand for trelagliptin is Zafatek® (Takeda Pharmaceutical Company Limited, approved by Japan’s PMDA in March 2015 the world’s first once-weekly oral antidiabetic). LuciTrelag, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centres, and endocrinology clinics.
What is the generic name of LuciTrelag?
The generic name of LuciTrelag is trelagliptin. LuciTrelag is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for trelagliptin manufactured in Laos. LuciTrelag is formulated as a 100 mg oral tablet in a 16-tablet blister pack a once-weekly, fixed-dose DPP-4 inhibitor providing approximately 4 months (16 weeks) of continuous therapy per carton. The originator reference brand is Zafatek® (Takeda Pharmaceutical Company Limited, Japan PMDA-approved March 2015, world’s first once-weekly oral DPP-4 inhibitor). Mediaid Pharmacy distributes LuciTrelag globally with worldwide shipping to patients, diabetes centres, endocrinology clinics, and hospital pharmacy departments. Browse the full diabetes medicines range at Mediaid Pharmacy for additional treatment options.
What is the difference between LuciTrelag (Trelagliptin) and Zafatek (Trelagliptin)?
LuciTrelag and Zafatek® both contain trelagliptin as the active pharmaceutical ingredient and share the same once-weekly DPP-4 inhibitor mechanism of action for type 2 diabetes mellitus. Zafatek® is the originator brand developed and marketed by Takeda Pharmaceutical Company Limited, approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in March 2015 as the world’s first once-weekly oral DPP-4 inhibitor and the first once-weekly oral antidiabetic agent approved globally. LuciTrelag is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied in 100 mg once-weekly oral tablets in a 16-tablet blister pack, available through Mediaid Pharmacy for international procurement by specialist diabetes centres and patients in regions where Zafatek® may be unavailable or cost-prohibitive. For the full range of diabetes medicines at Mediaid Pharmacy, browse the complete collection for worldwide delivery.
How is LuciTrelag (Trelagliptin) taken?
LuciTrelag (Trelagliptin) is taken orally as one 100 mg tablet once weekly, on the same designated day each week, at any time of day, with or without food. Swallow the tablet whole with water. Choose a specific day of the week (for example, every Sunday or every Monday) and administer LuciTrelag consistently on that day to maintain DPP-4 inhibition above 80% throughout the 7-day dosing interval. If a dose is missed, take it as soon as it is remembered on the same missed day; if it is not remembered until the following day, skip the missed dose and resume the regular once-weekly schedule on the next designated dosing day do not take two doses within the same week. For patients with normal to mildly impaired renal function (eGFR ≥30 mL/min/1.73 m²), the standard dose is 100 mg once weekly. For patients with moderate-to-severe renal impairment (eGFR <30 mL/min/1.73 m²), dose reduction to 50 mg once weekly is required. LuciTrelag is not recommended in patients with end-stage renal disease (ESRD) or on dialysis consult the treating endocrinologist before prescribing in any patient with significant renal comorbidity.
What are the side effects of LuciTrelag (Trelagliptin)?
The most commonly reported adverse reactions with trelagliptin in Phase 3 clinical trials include nasopharyngitis and upper respiratory tract infections. Urinary tract infections (UTIs) have also been reported. Hypoglycaemia does not occur with LuciTrelag as monotherapy due to its strictly glucose-dependent mechanism of insulin secretion potentiation; when combined with a sulfonylurea or insulin, hypoglycaemia risk increases and dose reduction of the sulfonylurea or insulin should be considered. Serious adverse reactions reported as class effects for DPP-4 inhibitors include severe hypersensitivity reactions (anaphylaxis, angioedema, exfoliative skin conditions) and acute pancreatitis discontinue LuciTrelag immediately if either is suspected. Always discuss the complete safety profile, hypoglycaemia risk with combination therapy, pancreatitis history, and hypersensitivity history with the treating endocrinologist before and throughout LuciTrelag (Trelagliptin) treatment.
Is LuciTrelag (Trelagliptin) safe for patients with kidney disease?
LuciTrelag (Trelagliptin) can be used in patients with mild renal impairment (eGFR 60–89 mL/min/1.73 m²) at the standard 100 mg once-weekly dose without adjustment. However, because trelagliptin is primarily eliminated renally as unchanged drug, its plasma exposure (AUC) increases with declining renal function, and dose reduction to 50 mg once weekly is required in patients with moderate-to-severe renal impairment (eGFR <30 mL/min/1.73 m²). LuciTrelag (Trelagliptin) is not recommended in patients with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis due to insufficient pharmacokinetic and clinical data. This renal dose-adjustment requirement is an important clinical distinction from linagliptin a once-daily DPP-4 inhibitor that requires no dose adjustment at any stage of renal impairment due to its predominantly biliary/intestinal non-renal elimination pathway. Consult the treating endocrinologist and nephrologist for individualised guidance on antidiabetic regimen selection in patients with significant renal comorbidities, and browse the full selection of diabetes medicines at Mediaid Pharmacy for worldwide delivery.
How effective is Trelagliptin (LuciTrelag) for type 2 diabetes?
Trelagliptin has demonstrated statistically significant and clinically meaningful efficacy in its Phase 3 clinical trial programme. As monotherapy: in a 24-week Phase 3 trial in Japanese adults with type 2 diabetes, trelagliptin 100 mg once weekly achieved HbA1c reduction of 0.87% from baseline versus 0.11% with placebo (p<0.0001), with weight neutrality and no hypoglycaemia as monotherapy. DPP-4 inhibition exceeded 80% throughout the full 7-day dosing interval at steady state, confirming that once-weekly dosing delivers sustained and clinically adequate incretin enhancement without trough-level DPP-4 inhibition gaps. In Phase 3 combination studies with existing antidiabetic background therapy (metformin, sulfonylurea, or glinide), trelagliptin 100 mg once weekly produced statistically significant additional HbA1c reductions versus placebo at 24 weeks, consistent with the add-on efficacy profile of daily DPP-4 inhibitors. Fasting plasma glucose was also significantly reduced versus placebo at 24 weeks in monotherapy and combination trials. LuciTrelag delivers the same active ingredient trelagliptin at the approved 100 mg once-weekly oral dose, sourced through Mediaid Pharmacy with worldwide shipping. For the complete diabetes medicines range at Mediaid Pharmacy, browse the full portfolio for international delivery.
Can I order LuciTrelag (Trelagliptin) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Lucius Pharmaceuticals LuciTrelag 100 MG (Trelagliptin) tablets to patients, diabetes specialist centres, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciTrelag 100 MG (Trelagliptin) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.